Which has stronger valuation and earnings, OWLT or TELA?

TELA Bio has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Owlet $105.70M 1.26 -$39.68M -$0.75 N/A TELA Bio $80.28M 0.66 -$38.83M -$0.77 N/A

Is OWLT or TELA more profitable?

Owlet has a net margin of -8.61% compared to TELA Bio's net margin of -51.53%. Owlet's return on equity of -601.24% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Owlet -8.61% -601.24% -15.96% TELA Bio -51.53% -1,320.81% -59.39%

Do analysts recommend TELA or INGN?

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 86.44%. Given TELA Bio's higher possible upside, analysts plainly believe TELA Bio is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, TELA or INGN?

Inogen has higher revenue and earnings than TELA Bio. Inogen is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.66 -$38.83M -$0.77 N/A Inogen $354.30M 0.38 -$22.75M -$0.90 N/A

Is TELA or INGN more profitable?

Inogen has a net margin of -6.94% compared to TELA Bio's net margin of -51.53%. Inogen's return on equity of -13.17% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -51.53% -1,320.81% -59.39% Inogen -6.94% -13.17% -8.36%

Is TELA or APYX more profitable?

Apyx Medical has a net margin of -14.78% compared to TELA Bio's net margin of -51.53%. Apyx Medical's return on equity of -76.60% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -51.53% -1,320.81% -59.39% Apyx Medical -14.78% -76.60% -13.91%

TELA Bio (TELA) Competitors

$1.18 +0.09 (+8.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 0.00 (-0.08%)

As of 05:42 PM Eastern

Compare

TELA vs. OWLT, KRMD, INGN, APYX, and CNXU

Should you buy TELA Bio stock or one of its competitors? TELA Bio's main competitors and comparable companies include Owlet (OWLT), KORU Medical Systems (KRMD), Inogen (INGN), Apyx Medical (APYX), and Conexeu Sciences (CNXU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TELA Bio compare to Owlet?

Owlet (NYSE:OWLT) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Owlet has a net margin of -8.61% compared to TELA Bio's net margin of -51.53%. Owlet's return on equity of -601.24% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
TELA Bio	-51.53%	-1,320.81%	-59.39%

Owlet has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Owlet currently has a consensus price target of $15.00, indicating a potential upside of 229.60%. TELA Bio has a consensus price target of $2.20, indicating a potential upside of 86.44%. Given Owlet's higher probable upside, equities analysts plainly believe Owlet is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

TELA Bio has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70M	1.26	-$39.68M	-$0.75	N/A
TELA Bio	$80.28M	0.66	-$38.83M	-$0.77	N/A

In the previous week, TELA Bio had 1 more articles in the media than Owlet. MarketBeat recorded 1 mentions for TELA Bio and 0 mentions for Owlet. TELA Bio's average media sentiment score of 1.89 beat Owlet's score of 0.00 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Owlet	Neutral
TELA Bio	Very Positive

72.6% of Owlet shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 36.2% of Owlet shares are owned by company insiders. Comparatively, 5.1% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Owlet beats TELA Bio on 9 of the 14 factors compared between the two stocks.

How does TELA Bio compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 5.1% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

KORU Medical Systems has higher earnings, but lower revenue than TELA Bio. KORU Medical Systems is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	3.57	-$2.64M	-$0.04	N/A
TELA Bio	$80.28M	0.66	-$38.83M	-$0.77	N/A

KORU Medical Systems has a net margin of -4.03% compared to TELA Bio's net margin of -51.53%. KORU Medical Systems' return on equity of -10.63% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-4.03%	-10.63%	-6.51%
TELA Bio	-51.53%	-1,320.81%	-59.39%

KORU Medical Systems has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, KORU Medical Systems had 2 more articles in the media than TELA Bio. MarketBeat recorded 3 mentions for KORU Medical Systems and 1 mentions for TELA Bio. KORU Medical Systems' average media sentiment score of 1.90 beat TELA Bio's score of 1.89 indicating that KORU Medical Systems is being referred to more favorably in the media.

Company	Overall Sentiment
KORU Medical Systems	Very Positive
TELA Bio	Very Positive

KORU Medical Systems presently has a consensus target price of $7.00, indicating a potential upside of 118.75%. TELA Bio has a consensus target price of $2.20, indicating a potential upside of 86.44%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, equities research analysts clearly believe KORU Medical Systems is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

KORU Medical Systems beats TELA Bio on 12 of the 16 factors compared between the two stocks.

How does TELA Bio compare to Inogen?

TELA Bio (NASDAQ:TELA) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 5.1% of TELA Bio shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 86.44%. Given TELA Bio's higher possible upside, analysts plainly believe TELA Bio is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

TELA Bio has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Inogen has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

In the previous week, Inogen had 1 more articles in the media than TELA Bio. MarketBeat recorded 2 mentions for Inogen and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 1.89 beat Inogen's score of 1.23 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
Inogen	Positive

Inogen has higher revenue and earnings than TELA Bio. Inogen is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.66	-$38.83M	-$0.77	N/A
Inogen	$354.30M	0.38	-$22.75M	-$0.90	N/A

Inogen has a net margin of -6.94% compared to TELA Bio's net margin of -51.53%. Inogen's return on equity of -13.17% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Inogen	-6.94%	-13.17%	-8.36%

Summary

Inogen beats TELA Bio on 9 of the 17 factors compared between the two stocks.

How does TELA Bio compare to Apyx Medical?

TELA Bio (NASDAQ:TELA) and Apyx Medical (NASDAQ:APYX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Apyx Medical had 2 more articles in the media than TELA Bio. MarketBeat recorded 3 mentions for Apyx Medical and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 1.89 beat Apyx Medical's score of 1.33 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
Apyx Medical	Positive

TELA Bio has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

TELA Bio currently has a consensus target price of $2.20, suggesting a potential upside of 86.44%. Apyx Medical has a consensus target price of $6.60, suggesting a potential upside of 119.27%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Apyx Medical has lower revenue, but higher earnings than TELA Bio. Apyx Medical is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.66	-$38.83M	-$0.77	N/A
Apyx Medical	$52.84M	2.40	-$11.21M	-$0.20	N/A

Apyx Medical has a net margin of -14.78% compared to TELA Bio's net margin of -51.53%. Apyx Medical's return on equity of -76.60% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Apyx Medical	-14.78%	-76.60%	-13.91%

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 5.1% of TELA Bio shares are held by company insiders. Comparatively, 15.9% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Apyx Medical beats TELA Bio on 12 of the 17 factors compared between the two stocks.

How does TELA Bio compare to Conexeu Sciences?

TELA Bio (NASDAQ:TELA) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

94.4% of TELA Bio shares are held by institutional investors. 5.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Conexeu Sciences has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. Conexeu Sciences' return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Conexeu Sciences	N/A	N/A	N/A

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 86.44%. Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 332.90%. Given Conexeu Sciences' higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Conexeu Sciences has lower revenue, but higher earnings than TELA Bio. Conexeu Sciences is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.66	-$38.83M	-$0.77	N/A
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A

In the previous week, Conexeu Sciences had 3 more articles in the media than TELA Bio. MarketBeat recorded 4 mentions for Conexeu Sciences and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 1.89 beat Conexeu Sciences' score of -0.51 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
Conexeu Sciences	Negative

Summary

TELA Bio and Conexeu Sciences tied by winning 7 of the 14 factors compared between the two stocks.

Get TELA Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELA vs. The Competition

Export

Metric	TELA Bio	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$52.98M	$5.49B	$7.19B	$14.92B
Dividend Yield	N/A	1.79%	2.57%	11.71%
P/E Ratio	-1.53	25.26	274.09	25.35
Price / Sales	0.66	68.32	697.83	112.39
Price / Cash	N/A	32.78	77.71	51.48
Price / Book	7.38	5.96	10.37	6.25
Net Income	-$38.83M	$151.55M	$3.49B	$358.55M
7 Day Performance	29.49%	-1.60%	-1.78%	-2.07%
1 Month Performance	83.14%	-4.12%	-1.48%	-4.80%
1 Year Performance	-25.32%	8.63%	18.20%	5.44%

TELA Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELA TELA Bio	3.8725 of 5 stars	$1.18 +8.3%	$2.20 +86.4%	-31.0%	$52.98M	$80.28M	N/A	120	Positive News High Trading Volume
OWLT Owlet	2.6134 of 5 stars	$5.05 +1.4%	$15.00 +197.0%	-32.8%	$147.42M	$105.70M	N/A	106
KRMD KORU Medical Systems	3.9506 of 5 stars	$3.16 -2.8%	$7.00 +121.5%	-19.8%	$145.14M	$41.13M	N/A	80	Positive News Analyst Upgrade
INGN Inogen	0.8405 of 5 stars	$5.29 -2.5%	N/A	-39.3%	$140.26M	$348.67M	N/A	1,030	Positive News
APYX Apyx Medical	3.38 of 5 stars	$3.06 +0.2%	$6.60 +116.0%	+39.0%	$128.68M	$52.84M	N/A	270	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELA) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TELA Bio (TELA) Competitors

TELA vs. OWLT, KRMD, INGN, APYX, and CNXU

How does TELA Bio compare to Owlet?

Summary

How does TELA Bio compare to KORU Medical Systems?

Summary

How does TELA Bio compare to Inogen?

Summary

How does TELA Bio compare to Apyx Medical?

Summary

How does TELA Bio compare to Conexeu Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA vs. The Competition

TELA Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TELA Bio (TELA) Competitors

TELA vs. OWLT, KRMD, INGN, APYX, and CNXU

How does TELA Bio compare to Owlet?

Is OWLT or TELA more profitable?

Which has more volatility and risk, OWLT or TELA?

Do analysts prefer OWLT or TELA?

Which has stronger valuation and earnings, OWLT or TELA?

Does the media favor OWLT or TELA?

Do institutionals and insiders have more ownership in OWLT or TELA?

Summary

How does TELA Bio compare to KORU Medical Systems?

Do institutionals & insiders have more ownership in KRMD or TELA?

Which has better earnings & valuation, KRMD or TELA?

Is KRMD or TELA more profitable?

Which has more risk & volatility, KRMD or TELA?

Does the media favor KRMD or TELA?

Do analysts prefer KRMD or TELA?

Summary

How does TELA Bio compare to Inogen?

Do insiders & institutionals have more ownership in TELA or INGN?

Do analysts recommend TELA or INGN?

Which has more volatility and risk, TELA or INGN?

Does the media refer more to TELA or INGN?

Which has preferable earnings & valuation, TELA or INGN?

Is TELA or INGN more profitable?

Summary

How does TELA Bio compare to Apyx Medical?

Does the media refer more to TELA or APYX?

Which has more volatility & risk, TELA or APYX?

Do analysts recommend TELA or APYX?

Which has stronger valuation & earnings, TELA or APYX?

Is TELA or APYX more profitable?

Do insiders and institutionals have more ownership in TELA or APYX?

Summary

How does TELA Bio compare to Conexeu Sciences?

Do institutionals & insiders have more ownership in TELA or CNXU?

Is TELA or CNXU more profitable?

Do analysts recommend TELA or CNXU?

Which has higher earnings and valuation, TELA or CNXU?

Does the media prefer TELA or CNXU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA vs. The Competition

TELA Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools